This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Italy
ADIENNE Pharma & Biotech is a company dedicated to the treatment of rare and severe diseases, with particular attention to onco-haematology, autoimmune diseases, solid organ and bone marrow transplantations.
Adriacell is a biotechnology company focused on the research and development of new generation biopharmaceuticals for the diagnosis and treatment of cancer. Company's lead candidate ADRIAC36 is a tumor DNA-double strand breaking biomolecule.
Anabasis is a private, Milan based, biopharmaceutical company dedicated to the development of innovative therapies for the eye.
The initial focus is NGF (Nerve Growth Factor) for the treatment of diseases affecting both the anterior part of the eye, such as neurotrophic keratitis (NK) and dry eye, as well as the posterior part of the eye such as glaucoma. These diseases can lead to severe vision loss and blindness.
Domp
The initial focus is NGF (Nerve Growth Factor) for the treatment of diseases affecting both the anterior part of the eye, such as neurotrophic keratitis (NK) and dry eye, as well as the posterior part of the eye such as glaucoma. These diseases can lead to severe vision loss and blindness.
Domp
Areta International is a biotech company affiliated to Holding F.I.S., the parent company controlling F.I.S. ? Fabbrica Italiana Sintetici S.p.A., the largest Italian API manufacturer. Areta is involved in the development and manufacturing of investigational biotechnology and advanced therapy medicinal products. Areta holds an extensive experience in process optimization, cGMP manufacturing, aseptic filling, development of new analytical methods, quality control analysis, batch release, stability studies and regulatory affairs.
Bio3 Research s.r.l. is a private biopharmaceutical company, developing new proprietary compounds up to Phase I/Phase IIA stage in: cardiovascular field, tissue regeneration and nephrology. Development activity is ongoing in the area of cardiovascular disorders related to HMGB1 (High Mobility Group Box 1) over-expression.
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Biomarine Europe is the Italian affiliate of BioMarin Pharmaceutical Inc..
Bionucleon S.r.l., a drug discovery company, engaged in the discovery and development of oligo-based therapeutics for inflammatory diseases and angiogenic disorders. The company's lead compound (BN210) targets the Hepatoma related protein 3 (HRP-3) and have reached its pre-clinical studies.
BiosYnth Research Laboratories is engaged in the development of glycoconjugate vaccines for the prevention of bacterial meningitis in infants and young children due to Gram-negative and Gram-positive encapsulated bacteria.
Chrono Benessere S.r.l. (CB) is a startup company founded in 2010 operating and rapidly growing on integrated diagnostics and personalized medicine.
The company is capitalizing over 10 years? experience in R&D and to achieve new markets quickly has a strategic partnership with Woman Health Technology S.r.l. (WHT) which focuses on Woman?s Health by delivering value throughout the complete cycle of life.
CB and WHT both actively participate in every project-phase regarding same business interests from project design to project implementation and monitoring.
The company is capitalizing over 10 years? experience in R&D and to achieve new markets quickly has a strategic partnership with Woman Health Technology S.r.l. (WHT) which focuses on Woman?s Health by delivering value throughout the complete cycle of life.
CB and WHT both actively participate in every project-phase regarding same business interests from project design to project implementation and monitoring.
Congenia discovers and develops small-molecule compounds designed to target and modulate (activating or inhibiting) the activity of the permeability transition pore (PTP), mitochondrial target involved in cellular ageing, senescence and apoptosis.
CTI is a biopharmaceutical company focused on developing and commercializing novel agents that seek to improve the safety and efficacy of existing standard-of-care chemotherapies, and those that may have unique, new mechanisms to kill cancer cells. company's Pixantrone* is a novel aza-anthracenedione derivative with unique structural and physio-chemical properties.